# US 2015/0104449 A1 · Variant Immunoglobulins with Improved Manufacturability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104449 A1
- Document ID: US20150104449A1
- Status: Published application
- Kind: A1
- Application number: 14/589,066
- Filed: 2015-01-05
- Published: 2015-04-16
- Earliest claimed: 2009-08-21
- Assignees: Lonza Biologics PLC
- Applicants: Lonza Biologics PLC
- Inventors: Andreas Arnell; Jose Jimenez; Rebecca Michael; Yvette Stallwood; Jesus Zurdo
- Web page: https://patentgrep.com/patent/US20150104449A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 39/39591: {Stabilisation, fragmentation}
- C07K 2317/522: CH1 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.

## Claims

### Claim 1

A method of improving the manufacturability of an immunoglobulin, comprising;
identifying a parent immunoglobulin having a VL domain and a VH domain,
introducing a substitution into a framework aggregation-prone segment and/or a CDR3 aggregation-prone segment in the VL domain of the parent immunoglobulin, and/or
introducing a substitution into a framework region aggregation-prone segment and/or a CDR3 aggregation-prone segment in the VH domain of the parent immunoglobulin, and/or;
introducing a substitution into a constant region aggregation-prone segment in the CH1 domain of the parent immunoglobulin,
thereby producing a variant immunoglobulin having a VL domain and a VH domain which displays improved manufacturability relative to the parent immunoglobulin.

### Claim 2

A variant immunoglobulin comprising;
a light chain variable (VL) domain which comprises a substitution at framework (FR) aggregation-prone segment and/or a complementary determining region 3 (CDR3) aggregation-prone segment;
a heavy chain variable (VH) domain which comprises a substitution at a framework region aggregation-prone segment and/or a CDR3 aggregation-prone segment; and/or,
a heavy chain constant region 1 (CH1) domain which comprises a substitution at a CH1 aggregation-prone segment.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or a variant immunoglobulin according to claim 2 wherein the variant immunoglobulin displays both reduced aggregation propensity and increased productivity upon expression, relative to the parent immunoglobulin

### Claim 4 (depends on 3)

A variant immunoglobulin or a method according to claim 3 wherein the variant immunoglobulin displays an increase in productivity of at least 20% and a decrease in aggregation propensity of at least 30% relative to the parent immunoglobulin.

### Claim 5 (depends on 3, 4)

A variant immunoglobulin or a method according to claim 3 or claim 4 wherein a substitution is introduced in the VL domain of the parent immunoglobulin at the VL position 37 aggregation-prone segment and/or the VL position 45 aggregation-prone segment; and/or
a substitution is introduced in the VH domain of the parent immunoglobulin at the VH FR1 aggregation-prone segment; the VH position 95 aggregation-prone segment; and the VH CDR3 aggregation-prone segment.

### Claim 6 (depends on 5)

A variant immunoglobulin or a method according to claim 5 wherein the substitution is introduced at a position selected from the group consisting of 1, 17, 94, 95, 96, 100, 100d and 102 of the VH domain sequence and/or a position selected from the group consisting of 37, 45 and 46 of the VL domain sequence.

### Claim 7 (depends on 6)

A variant immunoglobulin or a method according to claim 6 wherein the residue at position 37 in the VL domain sequence is substituted for Q or N.

### Claim 8 (depends on 7)

A variant immunoglobulin or a method according to claim 7 wherein the VL domain comprises a L37Q substitution.

### Claim 9 (depends on 6, 7, 8)

A variant immunoglobulin or a method according to any one of claims 6 to 8 wherein the residue at position 45 in the VL domain sequence is substituted for E, K, R, Q or V.

### Claim 10 (depends on 9)

A variant immunoglobulin or a method according to claim 9 wherein the VL domain comprises a T45E, T45K, T45R, T45Q or T45V substitution.

### Claim 11 (depends on 6, 7, 8, 9, 10)

A variant immunoglobulin or a method according to any one of claims 6 to 10 wherein the residue at position 46 in the VL domain sequence is substituted for L or Y.

### Claim 12 (depends on 11)

A variant immunoglobulin or a method according to claim 11 wherein the VL domain comprises a T46L or T46Y substitution.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

A variant immunoglobulin or a method according to any one of claims 6 to 12 wherein the residue at position 1 in the VH domain sequence is substituted for E, Q, D, A or V.

### Claim 14 (depends on 13)

A variant immunoglobulin or a method according to claim 13 wherein the VH domain comprises a Q1E, Q1D, Q1A or Q1V substitution or an E1Q, E1D, E1A or E1V substitution.

### Claim 15 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14)

A variant immunoglobulin or a method according to any one of claims 6 to 14 wherein the residue at position 17 in the VH domain sequence is substituted for R.

### Claim 16 (depends on 15)

A variant immunoglobulin or a method according to claim 15 wherein the VH domain comprises a G17R substitution.

### Claim 17 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A variant immunoglobulin or a method according to any one of claims 6 to 16 wherein the residue at position 94 in the VH domain sequence is substituted for R.

### Claim 18 (depends on 17)

A variant immunoglobulin or a method according to claim 17 wherein the VH domain comprises a H94R substitution.

### Claim 19 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A variant immunoglobulin or a method according to any one of claims 6 to 18 wherein the residue at position 95 in the VH domain sequence is substituted for D.

### Claim 20 (depends on 19)

A variant immunoglobulin or a method according to claim 19 wherein the VH domain comprises a R95D substitution.

### Claim 21 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A variant immunoglobulin or a method according to any one of claims 6 to 20 wherein the residue at position 96 in the VH domain sequence is substituted for A.

### Claim 22 (depends on 21)

A variant immunoglobulin or a method according to claim 21 wherein the VH domain comprises a G96A substitution.

### Claim 23 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A variant immunoglobulin or a method according to any one of claims 6 to 22 wherein the residue at position 100d in the VH domain sequence is substituted for F, G, L, P or M.

### Claim 24 (depends on 23)

A variant immunoglobulin or a method according to claim 23 wherein the VH domain comprises a S100dF, S100dG, S100dL, S100dP or S100dM substitution.

### Claim 25 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A variant immunoglobulin or a method according to any one of claims 6 to 24 wherein the residue at position 102 in the VH domain sequence is substituted for A, F, H, I, L, V or Y.

### Claim 26 (depends on 25)

A variant immunoglobulin or a method according to claim 25 wherein the VH domain comprises a P102A, P102F, P102H, P1021, P102L, P102Y, P102V or S102V substitution.

### Claim 27 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A variant immunoglobulin or a method according to any one of claims 3 to 26 wherein the sequence of the variant immunoglobulin has up to 10 amino acid substitutions relative to the parent immunoglobulin sequence.

### Claim 28 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A variant immunoglobulin or a method according to any one of claims 3 to 27 wherein the sequence of the VH domain comprises substitutions in the VH FR1 aggregation-prone segment and the VH CDR3 aggregation-prone segment.

### Claim 29 (depends on 28)

A variant immunoglobulin or a method according to claim 28 wherein the sequence of the VH domain comprises substitutions at position 1 and position 102.

### Claim 30 (depends on 29)

A variant immunoglobulin or a method according to claim 29 wherein the residue at position 102 is substituted for A, F, H, I, L, V or Y and wherein the residue at position 1 is substituted for E, Q, D, A or V.

### Claim 31 (depends on 30)

A variant immunoglobulin or a method according to claim 30 wherein the VH domain comprises a P102Y substitution and a Q1A or Q1E substitution.

### Claim 32 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A variant immunoglobulin or a method according to any one of claims 3 to 31 wherein the sequence of the VH domain comprises substitutions in the VH position 95 aggregation-prone segment and the VH CDR3 aggregation-prone segment.

### Claim 33 (depends on 32)

A variant immunoglobulin or a method according to claim 32 wherein the sequence of the VH domain comprises substitutions at position 95 and position 102.

### Claim 34 (depends on 33)

A variant immunoglobulin or a method according to claim 33 wherein the residue at position 102 is substituted for A, F, H, I, L, V or Y and wherein the residue at position 95 is substituted for E or D.

### Claim 35 (depends on 34)

A variant immunoglobulin or a method according to claim 34 wherein the VH domain comprises a S102V substitution and a R95D substitution.

### Claim 36 (depends on 33, 34, 35)

A variant immunoglobulin or a method according to any one of claims 33 to 35 wherein the VH domain further comprises substitutions at positions 94 and 100.

### Claim 37 (depends on 36)

A variant immunoglobulin or a method according to claim 36 wherein the residue at position 94 is substituted for R and the residue at position 100 is substituted for F.

### Claim 38 (depends on 37)

A variant immunoglobulin or a method according to claim 37 wherein the VH domain comprises a H94R substitution and a V100F substitution.

### Claim 39 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A variant immunoglobulin or a method according to any one of claims 3 to 38 wherein the sequence of the VL domain of the variant immunoglobulin comprises substitutions in the position 37 aggregation-prone segment and the position 45 aggregation-prone segment.

### Claim 40 (depends on 39)

A variant immunoglobulin or a method according to claim 39 wherein the sequence of the VL domain of the variant immunoglobulin comprises substitutions at position 37 and position 45.

### Claim 41 (depends on 40)

A variant immunoglobulin or a method according to claim 40 wherein the residue at position 37 is substituted for Q or N and wherein the residue at position 45 is substituted for R, K or E.

### Claim 42 (depends on 41)

A variant immunoglobulin or a method according to claim 41 wherein the VL domain comprises a L37Q substitution and a Q45R substitution.

### Claim 43 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

A variant immunoglobulin or a method according to any to any one of claims 3 to 42 wherein the VL domain comprises a S102V substitution and a R95D substitution and the VL domain comprises a L37Q substitution and a Q45R substitution.

### Claim 44 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A variant immunoglobulin or a method according to any one of claims 3 to 43 wherein the VH domain comprises one or more substitutions in the VH position 95 aggregation-prone segment and the VL domain comprises one or more substitutions in the position 45 aggregation-prone segment.

### Claim 45 (depends on 44)

A variant immunoglobulin or a method according to claim 44 wherein the VH domain comprises substitutions at positions 94 and 95 and the VL domain comprises a substitution at position 46.

### Claim 46 (depends on 45)

A variant immunoglobulin or a method according to claim 45 wherein the residue at position 94 in the VH domain is substituted for R, K or T and the residue at position 95 in the VH domain is substituted for E or D and the residue at position 46 in the VL domain is substituted for K, R, H, F or S.

### Claim 47 (depends on 46)

A variant immunoglobulin or a method according to claim 46 wherein the VH domain comprises a H94R and an R95D substitution and the VL domain comprises a L46R substitution.

### Claim 48 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A variant immunoglobulin or a method according to any one of claims 3 to 47 wherein the VH domain of the variant immunoglobulin comprises two or more substitutions in the VH CDR3 aggregation-prone segment.

### Claim 49 (depends on 48)

A variant immunoglobulin or a method according to claim 48 wherein the VH domain comprises substitutions at positions 100d and 102.

### Claim 50 (depends on 49)

A variant immunoglobulin or a method according to claim 49 wherein the VH domain comprises S100dF and P102V substitutions; S100dM and P102V substitutions; S100dF and P102Y substitutions or S100dM and P102Y substitutions.

### Claim 51

A variant immunoglobulin or a method according to any one of the preceding claims wherein the variant immunoglobulin is humanised.

### Claim 52

A variant immunoglobulin or a method according to any one of the preceding claims wherein the variant immunoglobulin is expressed in a recombinant system.

### Claim 53

A variant immunoglobulin or a method according to any one of the preceding claims wherein the variant immunoglobulin is isolated and/or purified following expression.

### Claim 54

A variant immunoglobulin or a method according to any one of the preceding claims wherein the variant immunoglobulin is formulated with a pharmaceutically acceptable excipient.

### Claim 55

A method of assessing the manufacturability of an immunoglobulin comprising;
identifying the amino acid residue at one or more positions selected from the group consisting of positions 37, 45 and 46 in the VL domain of the immunoglobulin, positions 1, 17, 94, 95, 96, 100, 100d and 102, in the VH domain,
wherein the presence of a residue other than Q at position 37; E, K, R, Q or V, preferably K or R, at position 45, L or Y, preferably L, at position 46, in the VL domain of the immunoglobulin and/or;
the presence of a residue other than A, D, E, Q or V at position 1, R at position 17, Rat position 94, A at position 96, F, G, L, M or P, preferably F or M at position 100d, A, F, H, I, L, V or Y, preferably V or Y, at position 102, in the VH domain of the immunoglobulin,
is indicative that the manufacturability of the immunoglobulin are sub-optimal.

### Claim 56 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A method according to claim 55 comprising that the manufacturability of the immunoglobulin is sub-optimal and improving the manufacturability of the immunoglobulin by a method according to any one of claims 1 and 3 to 54.

### Claim 57 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

A method of preparing an immunoglobulin with improved manufacturability comprising;
providing a nucleic acid encoding a variant immunoglobulin produced by a method according to any one of claims 1 and 3 to 46,
expressing the nucleic acid under conditions to bring about production of said variant immunoglobulin, and recovering it.

### Claim 58 (depends on 57)

A method according to claim 57 comprising formulating the variant immunoglobulin into a composition including a pharmaceutically acceptable excipient.
